Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus Enzalutamide in first-line HRR-mutated mCRPC in China
ChiCTR2300078496Phase 2Recruiting
- Sponsor
- Ruijin Hainan Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) and prostate adenocarcinoma, sponsored by Ruijin Hainan Hospital. Primary endpoint: PSA50 response at 6 months. Started Dec 2023; status: recruiting.
02
Drugs
talazoparibenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300078496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078496.